Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 81

1.

Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.

Delsing Malmberg E, Johansson Alm S, Nicklasson M, Lazarevic V, Ståhlman S, Samuelsson T, Lenhoff S, Asp J, Ehinger M, Palmqvist L, Brune M, Fogelstrand L.

Leuk Lymphoma. 2018 Aug 2:1-9. doi: 10.1080/10428194.2018.1485910. [Epub ahead of print]

PMID:
30068244
2.

Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow.

Lazarevic V, Orsmark-Pietras C, Lilljebjörn H, Pettersson L, Rissler M, Lübking A, Ehinger M, Juliusson G, Fioretos T.

Blood. 2018 Feb 1;131(5):577-581. doi: 10.1182/blood-2017-07-793620. Epub 2017 Nov 30. No abstract available.

PMID:
29191917
3.

Signaling via Smad2 and Smad3 is dispensable for adult murine hematopoietic stem cell function in vivo.

Billing M, Rörby E, Dahl M, Blank U, Andradottír S, Ehinger M, Karlsson S.

Exp Hematol. 2017 Nov;55:34-44.e2. doi: 10.1016/j.exphem.2017.06.005. Epub 2017 Jun 27.

PMID:
28666967
4.

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

Kolstad A, Pedersen LB, Eskelund CW, Husby S, Grønbæk K, Jerkeman M, Laurell A, Räty R, Elonen E, Andersen NS, Brown PD, Kimby E, Bentzen H, Sundström C, Ehinger M, Karjalainen-Lindsberg ML, Delabie J, Ralfkiær E, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Kuittinen O, Niemann C, Geisler CH; Nordic Lymphoma Group.

Biol Blood Marrow Transplant. 2017 Mar;23(3):428-435. doi: 10.1016/j.bbmt.2016.12.634. Epub 2016 Dec 27.

5.

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.

Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH.

Br J Haematol. 2016 Nov;175(3):410-418. doi: 10.1111/bjh.14241. Epub 2016 Jul 5.

PMID:
27378674
6.

A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis.

Skov V, Burton M, Thomassen M, Stauffer Larsen T, Riley CH, Brinch Madelung A, Kjær L, Bondo H, Stamp I, Ehinger M, Dahl-Sørensen R, Brochmann N, Nielsen K, Thiele J, Jensen MK, Weis Bjerrum O, Kruse TA, Hasselbalch HC.

PLoS One. 2016 Aug 31;11(8):e0161570. doi: 10.1371/journal.pone.0161570. eCollection 2016.

7.

Transplantation of Haploidentical TcRaß-Depleted Hematopoietic Cells Allows for Optimal Timing and Sustained Correction of the Metabolic Defect in Children With Infantile Osteopetrosis.

Pronk CJ, Turkiewicz D, Vult von Steyern K, Ehinger M, Dykes J, Toporski J.

J Bone Miner Res. 2017 Jan;32(1):82-85. doi: 10.1002/jbmr.2921. Epub 2016 Sep 8.

8.

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.

Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Grønbæk K, Sundberg J, Pedersen LB, Ralfkiær E, Karjalainen-Lindsberg ML, Sundström C, Ehinger M, Geisler C, Jerkeman M.

Blood. 2016 Oct 6;128(14):1814-1820. doi: 10.1182/blood-2016-03-704023. Epub 2016 Jun 27.

9.

Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.

Hyrenius-Wittsten A, Sturesson H, Bidgoli M, Jonson T, Ehinger M, Lilljebjörn H, Scheding S, Andersson AK.

Genes Chromosomes Cancer. 2016 Nov;55(11):847-54. doi: 10.1002/gcc.22384. Epub 2016 Jul 4.

PMID:
27240832
10.

Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.

Malmberg EB, Ståhlman S, Rehammar A, Samuelsson T, Alm SJ, Kristiansson E, Abrahamsson J, Garelius H, Pettersson L, Ehinger M, Palmqvist L, Fogelstrand L.

Eur J Haematol. 2017 Jan;98(1):26-37. doi: 10.1111/ejh.12780. Epub 2016 Jun 8.

PMID:
27197529
11.

Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.

Pettersson L, Levéen P, Axler O, Dvorakova D, Juliusson G, Ehinger M.

Genes Chromosomes Cancer. 2016 Oct;55(10):750-66. doi: 10.1002/gcc.22375. Epub 2016 Jun 24.

PMID:
27191933
12.

Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation.

Lübking A, Vosberg S, Konstandin NP, Dufour A, Graf A, Krebs S, Blum H, Weber A, Lenhoff S, Ehinger M, Spiekermann K, Greif PA, Cammenga J.

Leuk Res Rep. 2015 Oct 17;4(2):72-5. doi: 10.1016/j.lrr.2015.10.001. eCollection 2015.

13.

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.

Damm JK, Gordon S, Ehinger M, Jerkeman M, Gullberg U, Hultquist A, Drott K.

Exp Hematol Oncol. 2015 Jan 26;4:4. doi: 10.1186/2162-3619-4-4. eCollection 2015.

14.

Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1 mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2A.

Karrman K, Castor A, Behrendtz M, Forestier E, Olsson L, Ehinger M, Biloglav A, Fioretos T, Paulsson K, Johansson B.

J Hematol Oncol. 2015 Apr 24;8:42. doi: 10.1186/s13045-015-0138-0.

15.

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.

Husby S, Ralfkiaer U, Garde C, Zandi R, Ek S, Kolstad A, Jerkeman M, Laurell A, Räty R, Pedersen LB, Pedersen A, Ehinger M, Sundström C, Karjalainen-Lindsberg ML, Delabie J, Clasen-Linde E, Brown P, Cowland JB, Workman CT, Geisler CH, Grønbæk K.

Blood. 2015 Apr 23;125(17):2669-77. doi: 10.1182/blood-2014-06-584193. Epub 2015 Mar 3.

16.

Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice.

Dahl M, Doyle A, Olsson K, Månsson JE, Marques ARA, Mirzaian M, Aerts JM, Ehinger M, Rothe M, Modlich U, Schambach A, Karlsson S.

Mol Ther. 2015 May;23(5):835-844. doi: 10.1038/mt.2015.16. Epub 2015 Feb 6.

17.

Prognostic marker analysis in pediatric intracranial ependymomas.

McLendon RE, Lipp E, Satterfield D, Ehinger M, Austin A, Fleming D, Perkinson K, Lefaivre M, Zagzag D, Wiener B, Gururangan S, Fuchs H, Friedman HS, Herndon JE 2nd, Healy P.

J Neurooncol. 2015 Apr;122(2):255-61. doi: 10.1007/s11060-014-1711-z. Epub 2015 Jan 7.

PMID:
25563815
18.

Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.

Askmyr M, Ågerstam H, Lilljebjörn H, Hansen N, Karlsson C, von Palffy S, Landberg N, Högberg C, Lassen C, Rissler M, Richter J, Ehinger M, Järås M, Fioretos T.

Blood Cancer J. 2014 Dec 12;4:e269. doi: 10.1038/bcj.2014.89.

19.

Safety of noninvasive brain stimulation in children and adolescents.

Krishnan C, Santos L, Peterson MD, Ehinger M.

Brain Stimul. 2015 Jan-Feb;8(1):76-87. doi: 10.1016/j.brs.2014.10.012. Epub 2014 Oct 28. Review.

20.

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.

Nordström L, Sernbo S, Eden P, Grønbaek K, Kolstad A, Räty R, Karjalainen ML, Geisler C, Ralfkiaer E, Sundström C, Laurell A, Delabie J, Ehinger M, Jerkeman M, Ek S.

Br J Haematol. 2014 Jul;166(1):98-108. doi: 10.1111/bjh.12854. Epub 2014 Mar 29.

Supplemental Content

Loading ...
Support Center